|
|
 |
|
Total Number of Holdings (excluding cash): 50
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
6,763 |
$1,313,442.23 |
7.49% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
44,827 |
$1,312,086.29 |
7.48% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
7,378 |
$1,221,206.56 |
6.97% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
23,460 |
$1,152,589.80 |
6.57% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
9,364 |
$1,084,913.04 |
6.19% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
2,391 |
$810,835.92 |
4.62% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
790 |
$729,730.90 |
4.16% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
2,174 |
$722,746.30 |
4.12% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
616 |
$710,463.60 |
4.05% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
1,415 |
$686,798.55 |
3.92% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
8,257 |
$683,762.17 |
3.90% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
5,316 |
$601,611.72 |
3.43% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
3,002 |
$573,652.18 |
3.27% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
48,125 |
$561,137.50 |
3.20% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
2,743 |
$536,613.09 |
3.06% |
| Organon & Co. |
OGN |
68622V106 |
Pharmaceuticals |
23,564 |
$482,355.08 |
2.75% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
4,393 |
$477,914.47 |
2.73% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,150 |
$320,845.00 |
1.83% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
1,397 |
$277,458.17 |
1.58% |
| Perrigo Company Plc |
PRGO |
G97822103 |
Pharmaceuticals |
7,623 |
$211,538.25 |
1.21% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
598 |
$210,298.66 |
1.20% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
2,864 |
$182,035.84 |
1.04% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
6,222 |
$172,100.52 |
0.98% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
6,490 |
$171,725.40 |
0.98% |
| Prestige Consumer Healthcare Inc. |
PBH |
74112D101 |
Pharmaceuticals |
1,878 |
$139,197.36 |
0.79% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
1,033 |
$126,284.25 |
0.72% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
8,277 |
$119,768.19 |
0.68% |
| Arcellx, Inc. |
ACLX |
03940C100 |
Biotechnology |
1,512 |
$116,257.68 |
0.66% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
4,828 |
$114,568.44 |
0.65% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
521 |
$105,023.18 |
0.60% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
796 |
$102,827.28 |
0.59% |
| Exact Sciences Corporation |
EXAS |
30063P105 |
Biotechnology |
1,445 |
$94,705.30 |
0.54% |
| Rhythm Pharmaceuticals, Inc. |
RYTM |
76243J105 |
Biotechnology |
1,915 |
$95,022.30 |
0.54% |
| Ultragenyx Pharmaceutical Inc. |
RARE |
90400D108 |
Biotechnology |
1,608 |
$94,453.92 |
0.54% |
| Intra-Cellular Therapies, Inc. |
ITCI |
46116X101 |
Biotechnology |
1,196 |
$90,154.48 |
0.51% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,947 |
$89,717.76 |
0.51% |
| MoonLake Immunotherapeutics (Class A) |
MLTX |
61559X104 |
Biotechnology |
1,724 |
$88,165.36 |
0.50% |
| Merus NV |
MRUS |
N5749R100 |
Biotechnology |
1,715 |
$85,990.10 |
0.49% |
| Nuvalent, Inc. (Class A) |
NUVL |
670703107 |
Biotechnology |
988 |
$86,400.60 |
0.49% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
7,268 |
$86,779.92 |
0.49% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
964 |
$81,843.60 |
0.47% |
| Sarepta Therapeutics, Inc. |
SRPT |
803607100 |
Biotechnology |
650 |
$81,022.50 |
0.46% |
| Blueprint Medicines Corporation |
BPMC |
09627Y109 |
Pharmaceuticals |
889 |
$79,032.10 |
0.45% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
1,839 |
$77,587.41 |
0.44% |
| Viking Therapeutics, Inc. |
VKTX |
92686J106 |
Biotechnology |
1,079 |
$72,001.67 |
0.41% |
| IDEAYA Biosciences, Inc. |
IDYA |
45166A102 |
Biotechnology |
1,860 |
$69,675.60 |
0.40% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
3,578 |
$58,392.96 |
0.33% |
| Beam Therapeutics Inc. |
BEAM |
07373V105 |
Biotechnology |
2,105 |
$55,361.50 |
0.32% |
| CRISPR Therapeutics AG |
CRSP |
H17182108 |
Biotechnology |
987 |
$48,303.78 |
0.28% |
| Arvinas, Inc. |
ARVN |
04335A105 |
Biotechnology |
1,808 |
$45,290.40 |
0.26% |
| US Dollar |
$USD |
|
Other |
21,343 |
$21,342.81 |
0.12% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|